In a subgroup of patients with KRAS-mutant NSCLC in the phase III CheckMate 057 trial, patients with KRAS/STK11 co-mutations demonstrated significantly lower response rates than patients with KRAS/TP53 adenocarcinomas [19]. This evidence concerns the gene STK11 and non-small cell lung carcinoma.